Search Results

January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline Sanofi and Exscientia announced today a groundbreaking research collaboration and license agreement to develop

a set of 7 cannabinoid ligands (both natural and synthetic) to validate and optimize the assay. Because Tag-lite® is based on FRET, we have collaborated with BMG Labtech to develop an application note It bears a hydrophilic fluorophore compatible with the terbium donor in TR-FRET assays. Figure 2.Assay Principle: TR-FRET assay using CELT-335, a dual (CB1/CB2) fluorescent ligand that serves Comparison of binding affi nities using radioligand binding or TR-FRET assays.

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development

June 2022 "We’re delighted to welcome Dr Ed Brennan as our new Vice President, Head of Clinical Development Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID Executive Leadership Team Established with Demonstrated Success in Clinical, Regulatory and Commercial Development has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop

medicinal chemistry paved the way to co-founding Celtarys , a company now shaping the future of GPCR assay Over time, she developed a fascination with how molecules influence biology and how that chemistry could The academic group Maria worked with had developed a technology that allowed for flexible, fast synthesis GPCR, is helping researchers worldwide gain access to customized, reliable assay tools without the delays and frustrations that often plague probe development. 👉 Learn more about Celtarys’ science-driven solutions

Yamina’s Corner opens for strategic consulting, and our partner Celtarys unveils a robust TR-FRET assay Yamina’s Corner delivers GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking programs from hit validation through development candidate selection Visit Yamina’s Corner Now CELT-335 - Celtarys Validates New Assay for CB1/CB2 Screening Dr. GPCR partner Celtarys Research has validated a TR-FRET assay for cannabinoid receptor ligands using their

Celtarys Research expands its assay tools with CELT-419 for D3 receptor studies, and Dr. fuel confidence and fluency Move beyond theory to apply selectivity, ADME, and early safety in real development translational PK/PD   Subscribe to The Kenakin Brief Fluorescent Probe CELT-419 Powers D3R Binding Assays Celtarys Research presents CELT-419, a nanomolar-affinity fluorescent ligand optimized for D3 receptor assays With strong signal stability, HTS compatibility, and broad assay versatility, CELT-419 is designed for

Maria Majellaro, highlighting their fluorescent ligand tools for live-cell GPCR assays.   Maria Majellaro of Celtarys shares how her team translates medicinal chemistry into practical GPCR assay Introducing Celtarys - Probe Development via Conjugation Strategies   Celtarys Research's first article provides a detailed examination of conjugation strategies to develop high-performance fluorescent probes It emphasizes scaffold selection, linker optimization, and assay compatibility to enhance target binding

(e.g G protein recruitment assay [6], mini-G recruitment assay [7], GRK and β-arrestin recruitment assays [8]), G protein activation (e.g TRUPATH assay [9]), receptor trafficking ( e.g FYVE assay [10]),  β-arrestin  YEN assay [13]), among others. pharmacological activity, allowing for the determination of drug kinetics—a critical aspect in drug development Some innovative solutions have been the development of the BERKY and the ONE-GO biosensors, designed

Plus, Celtarys explores ligand selection for better assays, and co-founder Dr. Radioligands – Assay Smarter Celtarys explores how fluorescent ligands enable safer, high-throughput Learn how these tools help retain assay integrity while eliminating radioactivity—perfect for next-gen Maria Majellaro reveals how Celtarys evolved from a vision into a company solving real-world assay problems

Corner, Yamina's Corner, biotech, systems thinking, signal transduction, operational excellence, drug development

This emphasis may have caused other signaling pathways to be overlooked due to a need for adequate assay This further underscores the need for advanced assay technologies and a deep understanding of cellular Recently, several high-throughput screening (HTS) assays for ERK activation have been developed, each Each assay offers unique advantages for detecting ERK activation, contributing to the broader toolkit In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new

The assays are running, data is flowing in from your CROs or your internal labs , yet progress stalls This disconnect frequently leads to: Underperforming assays. I'll help write CRO scopes, meticulously review assay data, flag risks early, and keep your programs Systems That Drive Progress:  From assay tracking to data workflows, I design simple, scalable tools

Sometimes when you’re in the field you forget the importance GPCRs holds in drug development as a whole After all, a good tool makes a good assay, and a good assay improves research capacity. She gave us an overview of the drugs she has participated in developing throughout her career, highlighting Xiaoyu Zhang showed great insight into new ligands for new E3 ligases for PROTAC development.

Dual-epitope tagged constructs (N-term FLAG, C-term 1D4) Compatible with multiple readouts: proximity, immuno assays ______ Keyword Cloud : GPCR scientist network , GPCR online course , GPCR data platform , multiplex assays

The Tools to Detect Them Using the multiplexed GPCR library and Luminex assay , researchers can now: GPCR ecosystem , multiplex assays

Four hundred plates of assays, concentration-response curves, and mutagenesis screens are standard. _____ Keyword Cloud: GPCR scientist network , GPCR training program , mentorship in science , GTPγS assay

GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. Sakmar Lab’s Toolkit Goes Public The latest podcast features a discussion about a scalable GPCR-RAMP assay

Every day spent misunderstanding what your assays are truly showing you can lead to costly missteps—wasted Kenakin’s kinetic insights help you translate assay readouts into actionable knowledge that keeps your ’t Let Outdated Models Slow Your Next Program The analytical tools that shaped traditional affinity assays You’ll gain clarity that accelerates your path from discovery to clinic: Know when your assays truly

Let's explore the newest developments in GPCR research and community news together! Participants will acquire knowledge in: The powerful applications of new cellular assays to determine Modules: October 31st: The Eyes to See- The Importance of Pharmacologic Assays. Exclusive Deal for Scientists in Developing Nations If you reside and work in a developing country, complete and therapeutic strategies for tumor-induced kidney pathologies Methods & Updates in GPCR Research Development

I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising arrives too fast and too fragmented CROs deliver output without clear integration Teams chase the wrong assays Here’s what I bring: Biology-First Strategy I’ve designed GPCR assays, led collaborations across research

pipes instrument outputs into a central hub — where QC, analysis, consumption and consolidation across assays GPCR Drug Discovery The only way out for GPCR drug discovery programs isn’t more people or shinier assays The Hidden Costs of Poor Drug Discovery Data Management Stop pretending more hires or new assays will

Dates:  October 3 to 31, 2024 What You’ll Master during the five sessions: Utilizing new cellular assays GPCRs and mRNA antigens enable drug discovery and development Mapping GPCR-RAMP complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics Optimizes the Joint Development of New Drugs Using Intralinks’ Virtual Data Room   GPCR Events, Meetings, and Webinars 4th Transatlantic ECI GPCR Symposium September 18, 2024 | FREE Webinar - The value of GPCR cell-based assays

visualizing intermediate states with triple-color FRET, and deorphanizing targets using the new G(z)ESTY assay G(z)ESTY as an optimized cell-based assay for initial steps in GPCR deorphanization .  

activation state of G protein-coupled receptors are a useful addition to the molecular pharmacology assay the detection of both (partial) agonism and inverse agonism on living cells in a microplate reader assay better correlated with binding affinity values that were measured in radioligand competition binding assays biosensor in membranes might be a ready-to-use, high-throughput alternative for radioligand binding assays that in addition can also detect ligand efficacies with comparable values as the intact cell assay."

8 and colon formation, and cell migration and invasion were detected by wound healing and transwell assays Western blot and RT–qPCR assays were carried out to measure the downstream factors of the interaction The effect of CCL25 on the development of SACC in vivo was examined by a xenograft tumor model in nude

the cell ✅ Tools for evaluating scaffold permeability using modern, cost-effective pharmacokinetic assays In a traditional assay, they look the same. But in vivo? The good news: we now have reliable, low-cost assays to find out —Kenakin walks through the essential

membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop In Episode 166, Ben Clements dives into opioid pharmacology, GPCR-targeted PAMs, and how old-school assays

analogies (think batteries and balance scales), Terry reveals why different tissues—and even different assays—can